La revolución cuántica no se detiene. Si los ordenadores cuánticos prometen transformar el procesamiento de datos y la criptografía, los termómetros cuánticos apuntan a un cambio igual de profundo en cómo medimos la temperatura, desde los laboratorios …
En las aguas cristalinas del Mediterráneo, ocultas bajo la superficie, se extienden auténticos bosques submarinos: las praderas de posidonia oceánica. Aunque muchos las confunden con algas, se trata en realidad de plantas marinas con raíces, tallos y hojas, que desempe&nt …
While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.
Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed Read More »
The Basel area is home to over 800 life sciences companies, including Novartis and Roche, according to nonprofit Basel Area Business & Innovation. The nonprofit’s CEO and a BeOne Medicines executive discuss the location’s evolution, advantages and future.
Basel Life Sciences Scene Embraces International Companies, Startups Read More »
The upheaval of the Health and Human Services workforce and leadership leaves much to be desired in terms of delivery, recently retired FDA Chief Information Officer Vid Desai tells BioSpace, but the regulatory agency is evolving to be more open to much needed change.
‘Chaotic’ HHS Overhaul a Wrecking Ball Toward a Better FDA: Former CIO Read More »
The FDA is undergoing a major transformation in its drug approval processes, regulatory oversight and transparency initiatives. This webinar explores the implications of these reforms and what they mean for innovation, compliance and strategy in the biopharma industry.
Webinar: FDA in 2025: Navigating an Uncertain Regulatory Future Read More »
The Medicare giant likes what it’s seen in the first two weeks of open enrollment. But there are steps it can take if membership growth starts getting out of hand, executives said.
The general manager for the business says building a market is something the medtech giant knows how to do.
Medtronic’s Jason Fontana on ramping up renal denervation Read More »
According to reporting from Reuters, reviewers at the agency pointed to an inability to differentiate from placebo to justify rejecting the drug, but an FDA office director approved the drug anyway.
FDA Overruled Reviewers in Approving Stealth’s Barth Syndrome Treatment Read More »
Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?
